Introduction
Proton pump inhibitors (PPIs) are among the most frequently prescribed drugs. In 2012, this class ranked in the top 10 national health-related drug expenditures in United States [1] . The proportion of PPI use is also high in some European countries. In Spain, omeprazole ranked number one in drug sales in 2010, representing 5.5% of total drug packaging invoiced [2] .
The use of antiulcer agents in Spain has increased almost four times since the year 2000, primarily due to an increase in PPI use [2] . Similar trends are seen in other countries including the Netherlands, Iceland, Denmark, United Kingdom, Belgium, France and Australia [2] [3] [4] [5] .
Health care providers are increasingly prescribing PPIs for prolonged, sometimes lifetime, use, often without appropriate indications [6] . Furthermore, in several countries several PPIs are available over-the-counter, which encourages their consumption especially for unapproved indications [7] .
Many studies have been published on the rate of inappropriateness of PPI in both hospitalized and primary care patients, ranging from 27% to 81% [8] [9] .
Even if PPI are usually considered as safe, there is a growing concern for a range of potential adverse effects due to chronic PPI therapy [6, 10] . More precisely, recent evidence suggests that long term use of PPIs may increase the risk of dementia [11] [12] chronic kidney diseases [13] [14] and cardiovascular events such as strokes or myocardial infarctions [15] [16] . Because new data on biological and clinical experiments with PPI have been published during the same period, we propose, after a summary of these complications, an integrative overview of the potential biological mechanisms involved.
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Drug safety issues related to PPIs are increasing
Many pharmacoepidemiological studies described potential adverse effects of PPI long-term use (Table 1) . Over the past 3 years, safety issues related to neurological disorders have also been described, concerning the potential involvement of PPI as a putative factor of dementia, especially in elderly people. The first study published in 2015 was performed on data from a longitudinal multicenter cohort study in elderly primary care patients, the German Study
Aging, Cognition and Dementia in primary care (AgeCoDe) including 3327 communitydwelling persons aged > 75 years [17] . The use of PPI had a significantly increased risk of any dementia (HR =1.38) and Alzheimer disease (HR=1.44). Of the covariates included in the study, the known risk factors, age, the presence of ApoE4 allele, depression, diabetes, and stroke were found to increase significantly the risk of any dementia and/or Alzheimer disease [17] .
The study of Gomm et al. was performed on a longitudinal sample of patients free of dementia, aged of 75 years (n=73 679) from the largest German Insurance health database including inpatient and outpatient diagnosis (ICD codes) and drugs prescriptions [11] .
Using Cox regression with time-dependent variables, and after adjustment for potential confounding factors (age, sex, comorbidity and polypharmacy), a significantly increased risk of incident dementia was found in patients receiving regular PPI compared with the patients without PPI medication (HR= 1.44). As expected, anticholinergic drug use was also a risk factor of incident dementia (HR=1.80).
More recently, a study performed on a population-based cohort (7 863 PPI users) identified from Taiwan's national Health Insurance research Database confirmed the previous works of the two German studies [12] . After propensity score matching and adjustment for the called CANTAB which is well documented and validated to measure cognitive impairment in patients and healthy subjects [20] . Sixty healthy and young subjects (range 20-26 years) of either gender were randomly assigned into 6 groups (five groups according each IPP and one placebo group) [18] . A statistically and clinically significant impairment in visual memory, attention, executive function working and planning function was found. Interestingly, using a very large UK population cohort (n= 502 647 participants) assessed by three validated cognitive tests (verbal-numerical reasoning, memory and reaction time), participants in their middle age taking PPIs showed poorer cognitive function compared to non-takers [19] .
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Arora et al compared PPI users versus non-users from the Veterans Affairs Health Care New
York and observed a higher risk of CKD (incident <60ml/mi/1.73 m2) in PPIs users [13] . Xi et al aimed to assess the association of PPI use and the risk of long-term outcomes (including incident CKD, CKD progression and end stage renal disease) in those without intervening acute kidney injury (AKI), endorsing the possibility of a direct effect of PPI on chronic renal outcomes [22] . Lastly Klatte et al assessed the association between PPI use and the risk of CKD progression [23] .Using the Stockholm CREatinine Measurements database from 2006 to 2011, a cohort of new users of PPIs (n=105 305) and new users of H2 blockers (n=9 578) was identified. The primary outcome was the progression of CKD (defined as doubling of creatinine or decrease of eGFR of 30% or more). The secondary outcomes were end-stage renal disease and AKI. Users of PPIs had an increased risk for doubled levels of creatinine (HRa= 1,26) and a decrease in eGFR (HRa =1. 26 ). An increasing cumulative PPI use was associated with a higher risk for both primary outcome [23] . 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 9 Cardiovascular events have also been associated with PPIs. The association between PPI use and cardiovascular events has been extensively studied due to a possible pharmacokinetic interaction with antiplatelet therapy [24] [25] [26] [27] [28] . Recently several pharmacoepidemiological studies have been performed to address the effect of PPI alone [15, [29] [30] . A populationbased study from Ontario between 1996 and 2008 using a self-matched case series found that the initiation of PPIs was associated with a higher risk of acute myocardial infarction (OR =1,8) and heart failure (OR= 1.8) [29] . Similar findings were also described with histamine H2 receptor antagonists and benzodiazepines, with no known cardiac toxicity, restricting the added value of this work. Shi et al conducted a nationwide population-based study using the Taiwan National Health Insurance Research Database [30] . Two different study designs were performed to identify the association between PPI use and MI, the first using a propensity score-matching analysis (PS) and the second a case-crossover analysis. In the PS study, PPI use was associated with a 1.58-fold greater risk of MI. The association remains consistent across subgroups defined by age, gender and diabetes mellitus. In the second approach, PPI use was still associated with an increased risk for MI for 7-day and 14-day window period.
Using a complex approach for mining clinical data (clinical notes both inpatient and outpatient) for pharmacovigilance, Shah et al. demonstrated a two-fold increase of cardiovascular mortality in patients with gastroesophageal reflux disease exposed to PPI (HR = 2.00; 95% CI 1.07-3.78; P = 0.031) [15] . No cardiovascular risk was found with histamine H2-receptor antagonist (Shah, 2015) . A retrospective nationwide study on Taiwan national health insurance was performed to assess the risk of first-time ischemic stroke associated with PPI use [16] . Two analyses were applied, one using a propensity score analysis (PS) and the second using a nested case-control design. In the PS study, PPI use was associated with a Furthermore, the European Medicine Agency recently provided a special warning on the increase of circulating level of Chromogranin-A (CgA) in patients under PPIs [35] [36] . CgA is a soluble protein secreted from the adreno-medullary chromaffin granules. The proteolytic processing of CgA generates fragments (e.g catestatin, pancreastatin, vasostatin and serpinin) [37] . CgA and its fragments generate different angiogenic effects: CgA and vasostatin-1 exert anti-angiogenic effects CgA by inhibiting the TNF-elicited changes on endothelial cells and the proangiogenic Vascular Endothelial Growth Factor) [38] , whereas catestatin activates endothelial angiogenesis, vascularization, proliferation, cell chemotaxis and inhibits endothelial cell apoptosis [39] . An elevated plasma level of CgA has also been described in several cardiovascular pathological contexts as essential hypertension, hypertension secondary to parenchymal disease and chronic heart failure. Moreover, Chen et al.
demonstrated that CgA induces calcium-dependent secretion of all Weibel-Palade body constituents, especially endothelin-1 [40] . Endothelin-1 has been implicated in vascular dysfunction by pro-inflammatory and pro-atherosclerotic effects [41] and has also been associated with CKD [42] . Dhaun et al. suggested that endothelin-1 could impair kidney function by acting one of its receptor called ETA, leading to the development of proteinuria through its effects on podocytes (alterations in actin skeleton, loss of nephrin) [43] . Moreover, endothelin-1 induces the release of pro-inflammatory and profibrotic cytokines via the 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12 activation of mesangial cells, and also induces cell proliferation and the production of matrix proteins leading to glomerular sclerosis. Finally, endothelin-1 acts on renal inflammation via the macrophages infiltration in glomerulus. Yepuri et al. also provided other mechanisms leading to endothelial dysfunction such as impaired endothelial lysosomal acidification associated to impaired proteostasis [31] . Furthermore, nephrotoxicity of PPIs could be due to defects of lysosomal acidification and proteostasis, to hypomagnesemia or both, causing oxidative stress and leading to renal endothelial cell dysfunctions [44] .
Concerning neurological defects, observational data are now supported by fundamental biological studies. First, PPIs such as omeprazole have been shown to cross the blood-brain barrier [45] . Badiola et al. demonstrated using in vitro and in vivo models that lansoprazole can increase amyloid-β peptides, which is one of the major pathological hallmarks in Alzheimer disease [46] . Moreover, Fallahzadeh et al. hypothesized that PPIs could inhibit the V-ATPases on microglial lysosomes and lead to a basification of lysosomes, hampering degradation of amyloid-β peptides [47] . Another factor increasing dementia in patients chronically treated by PPIs might be a vitamin B12 deficiency. Several studies described a decrease of vitamin B12 linked to prolonged use of PPIs, especially in elderly individuals [48] [49] . Indeed, reduced levels of vitamin B12 have been associated with cognitive impairment ( [50] [51] . A decrease of vitamin B12 enhances hyperhomocysteinemia, described to increase ADMA, which increases cardiovascular diseases that may cause cognitive decline, leading to Alzheimer disease [52] . Thus, cardiovascular impairment potentially induced by PPIs might also be considered as an important pathophysiological factor of dementia.
Finally, Marlicz et al. suggested the influence of PPIs on the gut microbiota as an alternative to explain an increased risk of chronic diseases linked to these molecules [53] . PPIs could affect the gut-vascular permeability leading to bacterial endotoxemia, described to strongly increase the risk of cardiovascular disease [54] . Moreover, composition of intestinal 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 13 microbiota has been recently proposed as a key factor leading to aging-associated alterations [55] , and could have a role in a cognitive decline by the so called 'gut-brain interactions' [56] .
To date, biological effects were mostly evaluated in vitro. Several questions regarding these studies need to be answered such as the relevancy of doses used in vitro compared to therapeutic dose range used in patients partly because lower protein concentrations in culture medium than in plasma [57] . Similarly, drug penetration in cells could be very different in vitro compared to in vivo conditions due to the use of the vehicle (dimethyl sulphoxide, DMSO) increasing cell membrane permeability. Future studies need to understand all the underlying mechanisms involved in adverse effects of PPIs by following biological markers such as chromogranin A, endothelin-1, magnesium, B12 vitamin or DDAH and ADMA.
Conclusion
Even though in vivo studies are still required to understand and clarify the underlying mechanisms of such effects, the available fundamental and clinical data regarding drug safety should be considered. Actions should be undertaken particularly because these drug safety issues meet a body of evidence around the misuse and overprescribing of PPIs worldwide. As written by Lanas, even if the most of these adverse events have been mainly detected in observational studies, these potential adverse events should not be dismissed [2] . The magnitude of the use of these compounds, the high level of inappropriate use prescription worldwide, together with their potential association with serious adverse events, although low in frequency, may represent vast numbers of patients in absolute terms.
From now, these preliminary data should impose a very cautious attitude in the prescription of PPIs, especially in elderly individual and/or in the context of chronic use, even though the mechanisms involved in reported safety issues still have to be clarified. Awareness should be 14 raised among prescribers both in hospital and primary care settings. Patients with PPIs prescription, especially those who are on long term therapy, should be regularly reviewed by their general practitioner. All patients admitted at hospital with a PPI prescription should also be reviewed for reassessment of the real need of maintaining their treatment. These educational initiatives should be implemented by regulatory authorities in order to limit inappropriate prescribing of PPI and keep these therapies well-used. Such initiatives should also be supported by warnings from regulatory authorities, especially given the recent safety concern raised about long-term use of PPI. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49   20   Table 1 Published positive pharmacoepidemiological studies assessing a potential association between IPP and adverse events (dementia, chronic kidney disease and vascular events such as stroke or myocardial infarction) Potential adverse effects 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 
